Anti-Inflammatory Drugs — NSAIDs, Corticosteroids, and Gout

Correct Answer

A) Prednisone

Rationale

Prednisone is pharmacologically inactive and must be converted by hepatic 11-beta-hydroxysteroid dehydrogenase type 1 to its active form, prednisolone, before it can bind glucocorticoid receptors. Prednisolone, methylprednisolone, and dexamethasone are all pharmacologically active as administered and do not require hepatic activation.

Correct Answer

C) Dexamethasone

Rationale

Dexamethasone has negligible mineralocorticoid activity, making it preferred when sodium retention and hypokalemia must be avoided — for example in cerebral edema management, fetal lung maturation, and congenital adrenal hyperplasia treatment. Hydrocortisone has equal glucocorticoid and mineralocorticoid potency and is the reference compound. Fludrocortisone has very high mineralocorticoid potency and is used exclusively for mineralocorticoid replacement. Prednisone has modest mineralocorticoid activity intermediate between hydrocortisone and dexamethasone.

Correct Answer

B) Fludrocortisone

Rationale

Fludrocortisone is classified as a synthetic mineralocorticoid. It has very high mineralocorticoid potency and negligible anti-inflammatory activity at clinically used doses, and is prescribed exclusively for mineralocorticoid replacement — most commonly in primary adrenal insufficiency alongside hydrocortisone. Dexamethasone and betamethasone are high-potency glucocorticoids with negligible mineralocorticoid activity. Methylprednisolone is an intermediate-acting glucocorticoid with minimal mineralocorticoid activity.

Correct Answer

D) Methylprednisolone

Rationale

Methylprednisolone sodium succinate is a water-soluble formulation of methylprednisolone that can be administered intravenously, making it the preferred glucocorticoid for acute indications requiring parenteral dosing — such as acute severe asthma, anaphylaxis adjunct therapy, and acute cellular organ rejection. Prednisone and prednisolone are oral formulations. Fludrocortisone is an oral mineralocorticoid without a meaningful anti-inflammatory role.

Correct Answer

A) Fluticasone

Rationale

Fluticasone is classified as an inhaled corticosteroid. Inhaled corticosteroids are synthetic glucocorticoids formulated for direct delivery to the airway mucosa, producing local anti-inflammatory effects with minimal systemic exposure. Salmeterol is a long-acting beta-2 adrenergic agonist, montelukast is a leukotriene receptor antagonist, and ipratropium is a short-acting muscarinic antagonist. All four are inhaled agents used in respiratory disease, but only fluticasone belongs to the inhaled corticosteroid class.

Correct Answer

C) Hydrocortisone

Rationale

Hydrocortisone serves as the reference compound in corticosteroid potency comparisons, assigned a glucocorticoid potency of 1 and a mineralocorticoid potency of 1. All other corticosteroids are expressed as multiples of this reference. For example, prednisone has approximately four times the glucocorticoid potency of hydrocortisone with less mineralocorticoid activity; dexamethasone has approximately 25 times the glucocorticoid potency with negligible mineralocorticoid activity. Hydrocortisone is also the preferred agent for physiological replacement in adrenal insufficiency because it replaces both glucocorticoid and mineralocorticoid function simultaneously at physiological doses.

Correct Answer

B) Glucocorticoids act by binding a cytoplasmic receptor that translocates to the nucleus and alters gene transcription; the resulting changes in protein expression take hours to develop

Rationale

Glucocorticoids are lipophilic molecules that cross cell membranes freely and bind to receptors located in the cytoplasm. Drug binding activates the receptor, which then translocates into the nucleus and regulates the transcription of target genes — increasing expression of anti-inflammatory proteins and decreasing expression of pro-inflammatory mediators. Because this mechanism depends on changes in gene transcription and the subsequent synthesis or degradation of proteins, the clinical effects develop over hours rather than minutes. This delayed onset distinguishes glucocorticoids from drugs that act directly on enzymes or receptors at the cell surface, where effects are typically seen within minutes. Option A is incorrect because most glucocorticoids are administered in their active form; prednisone is the exception that requires hepatic conversion, but this does not explain the hours-long delay common to all glucocorticoids. Option C is incorrect because glucocorticoids do not inhibit cyclooxygenase directly. Option D is incorrect because the delay reflects the time required for genomic effects, not the time to reach pharmacokinetic steady state.

Correct Answer

B) Glucocorticoids suppress both the cyclooxygenase and lipoxygenase pathways by blocking the release of arachidonic acid from membrane phospholipids, while nonsteroidal anti-inflammatory drugs block only the cyclooxygenase pathway

Rationale

Nonsteroidal anti-inflammatory drugs inhibit cyclooxygenase, blocking the synthesis of prostaglandins and thromboxane A2 — but the lipoxygenase pathway remains fully intact, allowing continued leukotriene production. Glucocorticoids act at a point upstream of both pathways: they induce inhibitors of phospholipase A2, the enzyme that releases arachidonic acid from membrane phospholipids. By reducing the availability of arachidonic acid — the shared substrate — glucocorticoids simultaneously suppress both the cyclooxygenase and lipoxygenase branches. This broader blockade of the arachidonic acid cascade, combined with additional effects on cytokine production and inflammatory cell recruitment, makes glucocorticoids more potent and broader anti-inflammatory agents than nonsteroidal anti-inflammatory drugs. Option A is incorrect because glucocorticoids do not inhibit cyclooxygenase directly. Option C is incorrect because lipophilicity determines receptor accessibility, not potency relative to nonsteroidal anti-inflammatory drugs. Option D is incorrect because glucocorticoids act through gene regulation, not direct cytokine neutralization in the bloodstream.

Correct Answer

A) Prednisone is a pharmacologically inactive prodrug that requires conversion to prednisolone by hepatic 11-beta-hydroxysteroid dehydrogenase type 1; in severe hepatic disease this conversion may be unreliable, so prednisolone — the active form — is given directly to bypass the activation step

Rationale

Prednisone is pharmacologically inactive until converted to its active form, prednisolone, by 11-beta-hydroxysteroid dehydrogenase type 1 in the liver. In patients with severe hepatic disease, hepatocyte function is compromised and this enzymatic conversion may be unreliable or reduced, leading to lower and unpredictable prednisolone plasma concentrations after prednisone administration. Prescribing prednisolone directly provides the active drug without depending on a potentially impaired hepatic activation step. The mineralocorticoid activities of prednisone and prednisolone are equivalent, and neither drug's bioavailability is substantially different by this mechanism.

Correct Answer

C) Ritonavir is a potent inhibitor of cytochrome P450 3A4, markedly reducing the first-pass hepatic metabolism of the fraction of inhaled fluticasone that is swallowed, raising systemic fluticasone exposure to concentrations that produce glucocorticoid excess

Rationale

Inhaled corticosteroids achieve their wide therapeutic window partly because the fraction of drug that is swallowed — from oropharyngeal deposition — undergoes near-complete first-pass hepatic extraction by cytochrome P450 3A4, limiting systemic bioavailability to negligible levels. Ritonavir is a potent inhibitor of cytochrome P450 3A4. When ritonavir is co-administered with inhaled fluticasone, hepatic first-pass metabolism of the swallowed fraction is blocked, raising systemic fluticasone exposure. Even though the inhaled dose appears small, the accumulation of drug that would normally be cleared on first pass is sufficient to produce clinically meaningful glucocorticoid excess — manifesting as iatrogenic Cushing syndrome with suppression of the hypothalamic-pituitary-adrenal axis. This interaction can also cause secondary adrenal insufficiency if fluticasone is then stopped.

Correct Answer

B) Inhaled corticosteroids deliver drug directly to airway mucosa at high local concentrations, while the swallowed fraction undergoes near-complete first-pass hepatic extraction by cytochrome P450 3A4, preventing systemic accumulation

Rationale

The pharmacokinetic advantage of inhaled corticosteroids rests on two complementary mechanisms. First, inhalation delivers drug directly to the target tissue — the inflamed airway mucosa — producing high local concentrations with a small dose. Second, the fraction of drug that is swallowed (from oropharyngeal deposition) or absorbed through the pulmonary vasculature undergoes rapid first-pass hepatic metabolism by cytochrome P450 3A4. Fluticasone propionate, for example, has near-zero oral bioavailability because of nearly complete first-pass hepatic extraction. The swallowed fraction that would otherwise contribute to systemic exposure is eliminated before reaching the systemic circulation. This pharmacokinetic design produces a therapeutic window far wider than any equivalent systemic dose could provide.

Correct Answer

D) Inhaled corticosteroids prevent the beta-2 receptor downregulation that occurs with prolonged long-acting beta-2 agonist use, preserving bronchodilator responsiveness, while long-acting beta-2 agonists provide complementary bronchodilation through a mechanism that operates independently of the anti-inflammatory pathway — addressing the two pharmacological limitations that neither drug alone can overcome

Rationale

The synergy between inhaled corticosteroids and long-acting beta-2 agonists rests on two complementary pharmacological limitations that each drug class addresses for the other. First, prolonged stimulation of beta-2 receptors by a long-acting beta-2 agonist causes receptor downregulation over time, reducing bronchodilator efficacy. Inhaled corticosteroids upregulate beta-2 receptor expression, preventing this downregulation and preserving the bronchodilator response. Second, inhaled corticosteroids suppress airway inflammation effectively but do not produce bronchodilation — they do not relax airway smooth muscle acutely. Long-acting beta-2 agonists provide this complementary bronchodilator effect through a pathway that is mechanistically independent of the anti-inflammatory action of corticosteroids. Together, the combination addresses both airway inflammation and airway obstruction, which is why it outperforms doubling the inhaled corticosteroid dose and why long-acting beta-2 agonists must never be used as asthma monotherapy without an inhaled corticosteroid.

Correct Answer

A) Exogenous glucocorticoids suppress hypothalamic and pituitary corticotropin-releasing hormone and adrenocorticotropic hormone secretion through negative feedback; chronically low adrenocorticotropic hormone causes progressive adrenal cortical atrophy, leaving the adrenal gland unable to produce adequate cortisol when exogenous glucocorticoid is withdrawn

Rationale

Cortisol normally regulates its own production through negative feedback at the hypothalamus and anterior pituitary, suppressing corticotropin-releasing hormone and adrenocorticotropic hormone respectively. Exogenous glucocorticoids activate the same receptors and produce the same feedback signal, chronically suppressing adrenocorticotropic hormone secretion. Without adequate adrenocorticotropic hormone stimulation — the primary trophic signal for the adrenal cortex — the adrenal gland undergoes progressive atrophy over weeks to months. When exogenous glucocorticoids are withdrawn, both the hypothalamic-pituitary axis and the atrophied adrenal gland require time to recover. During this recovery period, the patient cannot mount a normal cortisol stress response, producing secondary adrenal insufficiency. This is the pharmacological basis for requiring a gradual taper after prolonged glucocorticoid therapy.

Correct Answer

C) On the off day, plasma glucocorticoid levels fall below the threshold for sustained hypothalamic-pituitary-adrenal feedback suppression, allowing transient axis recovery, while anti-inflammatory gene expression changes outlast the drug exposure and persist into the off day

Rationale

The hypothalamic-pituitary-adrenal axis is suppressed when plasma glucocorticoid concentrations remain persistently elevated. On an alternate-day dosing schedule, plasma drug levels decline on the off day, allowing the hypothalamus and pituitary to recover transiently from glucocorticoid feedback inhibition. This recovery window is sufficient to reduce the degree of adrenal cortical atrophy compared to continuous daily exposure. The anti-inflammatory benefit is preserved because the gene expression changes that underlie the therapeutic effect — including suppression of cytokine genes and induction of anti-inflammatory proteins — have a duration of action that extends well beyond the pharmacokinetic half-life of the drug. The therapeutic effect therefore persists into the off day even as the hypothalamic-pituitary-adrenal recovery is occurring.

Correct Answer

D) Granulomatous inflammation in giant cell arteritis can occlude the ophthalmic artery, causing rapid and irreversible vision loss; immediate corticosteroid treatment suppresses the vascular inflammation before this occurs, and biopsy histological findings persist for one to two weeks despite steroid treatment

Rationale

Giant cell arteritis is a granulomatous vasculitis affecting large and medium vessels, with a predilection for the branches of the external carotid artery and the ophthalmic circulation. The ophthalmic artery and posterior ciliary arteries supply the retina; granulomatous occlusion of these vessels can cause permanent bilateral blindness within hours of the first visual symptom. Because corticosteroids suppress the granulomatous inflammation that drives occlusion, they must be started immediately when the clinical picture is consistent with the diagnosis — without waiting for biopsy confirmation. Histological evidence of giant cell arteritis persists in the biopsy specimen for one to two weeks after corticosteroid initiation, so the diagnostic procedure remains informative even after treatment begins.

Correct Answer

B) Methylprednisolone acts through gene transcription, and the resulting anti-inflammatory effects take hours to become clinically apparent; bronchodilators provide immediate airway dilation that corticosteroids cannot replace in the acute phase

Rationale

Glucocorticoids exert their anti-inflammatory effects through genomic mechanisms — binding the glucocorticoid receptor, translocating to the nucleus, and altering gene transcription. The resulting changes in protein expression (reduced cytokine production, suppressed inflammatory cell recruitment, decreased vascular permeability) take hours to become clinically apparent, even after intravenous dosing. In the acute asthma setting, the patient needs immediate relief of bronchospasm that corticosteroids alone cannot provide on this timescale. Beta-2 adrenergic agonists such as albuterol relax airway smooth muscle within minutes through receptor-mediated cyclic adenosine monophosphate elevation. Corticosteroids complement this by reducing the underlying airway inflammation over subsequent hours, improving outcomes and reducing the risk of relapse. This is why corticosteroids are added to — not substituted for — bronchodilators in acute severe asthma.

Correct Answer

A) Eight weeks of prednisone at 30 mg daily suppressed hypothalamic and pituitary adrenocorticotropic hormone secretion, causing adrenal cortical atrophy; abrupt discontinuation left the adrenal gland unable to produce sufficient cortisol for normal physiological demands

Rationale

Prednisone at 30 mg daily for 8 weeks far exceeds the threshold for clinically meaningful hypothalamic-pituitary-adrenal axis suppression (prednisone equivalent above 20 mg daily for more than three weeks). The sustained negative feedback on hypothalamic corticotropin-releasing hormone and pituitary adrenocorticotropic hormone secretion causes progressive atrophy of the adrenal cortex — the gland decreases in size and secretory capacity because its primary trophic stimulus has been chronically suppressed. When prednisone is stopped abruptly, the patient's own adrenal glands cannot immediately resume normal cortisol production, producing secondary adrenal insufficiency. The symptoms — fatigue, nausea, anorexia, and orthostatic hypotension — reflect glucocorticoid deficiency. Mineralocorticoid production (aldosterone) is preserved in secondary adrenal insufficiency because it is regulated by the renin-angiotensin-aldosterone system rather than adrenocorticotropic hormone, which is why severe electrolyte abnormalities are less prominent than in primary adrenal insufficiency.

Correct Answer

C) Ritonavir inhibits cytochrome P450 3A4, blocking the hepatic first-pass metabolism that normally eliminates the swallowed fraction of inhaled fluticasone, raising systemic fluticasone concentrations to levels that produce glucocorticoid excess

Rationale

Inhaled fluticasone has near-zero oral bioavailability under normal circumstances because the fraction swallowed — deposited in the oropharynx during inhalation — undergoes near-complete first-pass extraction by cytochrome P450 3A4 in the intestinal wall and liver. Ritonavir is a potent inhibitor of cytochrome P450 3A4. When ritonavir is added, this first-pass elimination pathway is blocked, and the swallowed fluticasone fraction enters the systemic circulation largely intact. Although the absolute drug amount appears small, the resulting systemic glucocorticoid exposure is sufficient to suppress the hypothalamic-pituitary-adrenal axis and produce features of Cushing syndrome — moon face, truncal obesity, skin atrophy, and easy bruising. This interaction can also produce secondary adrenal insufficiency if fluticasone is then abruptly discontinued. Management requires substituting a corticosteroid with lower systemic bioavailability or one that is less dependent on cytochrome P450 3A4 for its clearance.